La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Halozyme Therapeutics Croissance future
Future contrôle des critères 5/6
Halozyme Therapeutics is forecast to grow earnings and revenue by 22% and 15.6% per annum respectively. EPS is expected to grow by 24% per annum. Return on equity is forecast to be 83.1% in 3 years.
Informations clés
22.0%
Taux de croissance des bénéfices
24.0%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 30.4% |
Taux de croissance des recettes | 15.6% |
Rendement futur des capitaux propres | 83.1% |
Couverture par les analystes | Good |
Dernière mise à jour | 07 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Aug 14Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar
Jul 17Halozyme Therapeutics: The Story Brightens
Jun 07Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Dec 09Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Oct 24Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 1,400 | 678 | N/A | N/A | 6 |
12/31/2025 | 1,145 | 512 | 627 | 633 | 9 |
12/31/2024 | 984 | 416 | 536 | 528 | 10 |
6/30/2024 | 873 | 337 | 408 | 420 | N/A |
3/31/2024 | 863 | 319 | 424 | 431 | N/A |
12/31/2023 | 829 | 282 | 373 | 389 | N/A |
9/30/2023 | 781 | 254 | 354 | 369 | N/A |
6/30/2023 | 774 | 234 | 293 | 306 | N/A |
3/31/2023 | 705 | 182 | 264 | 279 | N/A |
12/31/2022 | 660 | 202 | 235 | 240 | N/A |
9/30/2022 | 581 | 211 | 238 | 240 | N/A |
6/30/2022 | 487 | 366 | 290 | 292 | N/A |
3/31/2022 | 472 | 435 | 287 | 289 | N/A |
12/31/2021 | 443 | 403 | 298 | 299 | N/A |
9/30/2021 | 463 | 409 | 265 | 268 | N/A |
6/30/2021 | 412 | 229 | 150 | 152 | N/A |
3/31/2021 | 331 | 163 | 116 | 119 | N/A |
12/31/2020 | 268 | 129 | 53 | 55 | N/A |
9/30/2020 | 200 | 22 | -24 | -22 | N/A |
6/30/2020 | 180 | -40 | -60 | -58 | N/A |
3/31/2020 | 164 | -80 | -89 | -86 | N/A |
12/31/2019 | 196 | -72 | -89 | -85 | N/A |
9/30/2019 | 203 | -40 | -55 | -48 | N/A |
6/30/2019 | 182 | -43 | -43 | -38 | N/A |
3/31/2019 | 178 | -51 | -36 | -32 | N/A |
12/31/2018 | 152 | -80 | -54 | -49 | N/A |
9/30/2018 | 281 | 46 | 91 | 93 | N/A |
6/30/2018 | 319 | 76 | 130 | 132 | N/A |
3/31/2018 | 318 | 68 | N/A | 134 | N/A |
12/31/2017 | 317 | 63 | N/A | 134 | N/A |
9/30/2017 | 166 | -88 | N/A | -35 | N/A |
6/30/2017 | 134 | -120 | N/A | -64 | N/A |
3/31/2017 | 134 | -116 | N/A | -60 | N/A |
12/31/2016 | 147 | -103 | N/A | -50 | N/A |
9/30/2016 | 160 | -71 | N/A | -50 | N/A |
6/30/2016 | 149 | -67 | N/A | -58 | N/A |
3/31/2016 | 159 | -37 | N/A | -36 | N/A |
12/31/2015 | 135 | -32 | N/A | -37 | N/A |
9/30/2015 | 113 | -42 | N/A | -23 | N/A |
6/30/2015 | 107 | -38 | N/A | -19 | N/A |
3/31/2015 | 82 | -57 | N/A | -44 | N/A |
12/31/2014 | 75 | -68 | N/A | -48 | N/A |
9/30/2014 | 57 | -85 | N/A | -62 | N/A |
6/30/2014 | 59 | -84 | N/A | -61 | N/A |
3/31/2014 | 55 | -91 | N/A | -56 | N/A |
12/31/2013 | 55 | -83 | N/A | -49 | N/A |
9/30/2013 | 64 | -66 | N/A | -51 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: HALO's forecast earnings growth (22% per year) is above the savings rate (2.5%).
Bénéfices vs marché: HALO's earnings (22% per year) are forecast to grow faster than the US market (15.1% per year).
Croissance élevée des bénéfices: HALO's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: HALO's revenue (15.6% per year) is forecast to grow faster than the US market (8.8% per year).
Croissance élevée des revenus: HALO's revenue (15.6% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: HALO's Return on Equity is forecast to be very high in 3 years time (83.1%).